Astellas Pharma, Inc, Akebia Therapeutics, Inc, Lupin Limited, Ardelyx, Inc, and Vifor Pharma Management Ltd, among others, are leading players in the global hyperphosphatemia therapeutics market.
The global hyperphosphatemia therapeutics market would likely grow at a CAGR of 5.4% during 2022-2027. Advancements in research and treatment systems are expected to drive the global market. Asia, North America and Europe are likely to be key markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
|Headquarters:||Chuo City, Tokyo, Japan|
Astellas Pharma, Inc. is a pharmaceutical company that conducts business in over seventy nations across the globe. The company seeks to promote the Focus Area Approach devised to recognize opportunities to continually create novel drugs to address diseases with high unmet medical needs through focus on Modality and Biology. Offerings include XTANDI® (enzalutamide), XOSPATA® (gilteritinib), PADCEV® (enfortumab vedotin), Evrenzo® (roxadustat), Betanis®/Myrabetriq™/BETMIGA™ (mirabegron), Prograf® and Advagraf™/Graceptor®/ASTAGRAF XL™ (tacrolimus).
Akebia Therapeutics, Inc. is an expanding biopharmaceutical company with headquarters in Cambridge, Massachusetts; the company focuses on the commercialization and development of therapeutics for individuals with kidney disease.
Lupin Limited is an international pharmaceutical company that offers Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Today, Lupin is a major player in Japan, India, USA and other nations within EMEA, APAC, and LATAM. The company has a strong position in Anti-TB and Cephalosporin segments. Lupin focuses on establishing a significant pipeline in women’s health in USA, Neurology in Japan and Europe, Diabetes, Cardiac and Respiratory in India, and Dermatology and Ophthalmic in LATAM. Specialties include Complex Generics, Specialty Pharmaceuticals, APIs, Biotechnology, Biosimilars, Drug Delivery Systems, Biologics, and Global Formulations.
Ardelyx, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative first-in-class drugs that fulfil significant unmet medical needs.
|Headquarters:||St. Gallen, Switzerland|
Vifor Pharma Management Ltd. is a leading company in the domain of iron deficiency and nephrology, committed to introducing the next generation of therapies to address the full range of kidney disease, with focus on rare disease and dialysis. Specialties include Nephrology, Iron Deficiency, and Cardio-Renal therapies.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.